Revolution Medicines Financials - Benzinga

Revolution Medicines Inc

RVMDNASDAQ

Trade with Public

Trade with Public

$190.74

-2.12-1.1%

al cierre: Sep 23, 5:00 PM EST

$190.74

N/A

After hour: 4:30 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Revolution Medicines Financials

Revolution Medicines (RVMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(3.06) per share which missed the analyst consensus estimate of $(1.98) by 54.55 percent. This is a 133.59 percent decrease over losses of $(1.31) per

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Revolution Medicines Sees FY26 GAAP Operating Expenses $1.7B-$1.8B

Benzinga Newsdesk

PRO
Revolution Medicines Q1 EPS $(2.29) Misses $(1.82) Estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(2.29) per share which missed the analyst consensus estimate of $(1.82) by 25.82 percent. This is a 102.65 percent decrease over losses of $(1.13) per

Benzinga Newsdesk

Revolution Medicines: Q4 Earnings Insights

Benzinga Insights

PRO
Revolution Medicines Q4 EPS $(1.86) Misses $(1.58) Estimate. Cash And Equivalents $2.03B

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.86) per share which missed the analyst consensus estimate of $(1.58) by 17.87 percent. This is a 66.07 percent decrease over losses of $(1.12) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved